John C. Jacobs
Principal executive officer pay for John C. Jacobs, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Grouped by exact name match across filings; distinct people sharing a name would be merged — flag it and we'll split them.
Harmony Biosciences Holdings, Inc. (HRMY) FY2021–FY2023
Lagged peersTSR -24% vs peer group -8% over FY2021–FY2023
Aligned: pay fell with the stockCAP $1,960,526→-$5,020,055 while $100 invested went $115.00→$87.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $885,554 | $2.0M |
| FY2022 | $514,752 | $2.9M |
| FY2023 | $36,634 | -$5.0M |
A negative figure is not pay returned. Compensation Actually Paid re-values unvested equity every year, so when a stock falls, the write-down on awards granted earlier can exceed everything granted that year. How CAP is calculated
The company's "$100 invested" index ran $115.00 at FY2021 → $87.00 by FY2023 — an annualized return of -13.0%.
Harmony Biosciences Holdings, Inc. (HRMY) FY2020–FY2023
Tracked peersTSR $98.00→$87.00 vs peer group $113.00→$104.00 (FY2020–FY2023)
Aligned: pay fell with the stockCAP $6,392,185→-$5,020,055 while $100 invested went $98.00→$87.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $3.2M | $6.4M |
| FY2021 | $885,554 | $2.0M |
| FY2022 | $514,752 | $2.9M |
| FY2023 | $36,634 | -$5.0M |
A negative figure is not pay returned. Compensation Actually Paid re-values unvested equity every year, so when a stock falls, the write-down on awards granted earlier can exceed everything granted that year. How CAP is calculated
The company's "$100 invested" index ran $98.00 at FY2020 → $87.00 by FY2023 — an annualized return of -3.9%.
NOVAVAX INC (NVAX) FY2023–FY2025
Lagged peersTSR -95% vs peer group -9% over FY2023–FY2025
Paid for declineCAP $3,775,263→$6,310,790 while $100 invested went $121.00→$6.03 (FY2023–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $7.3M | $3.8M |
| FY2024 | $5.1M | $7.1M |
| FY2025 | $8.9M | $6.3M |
The company's "$100 invested" index ran $121.00 at FY2023 → $6.03 by FY2025 — an annualized return of -77.7%.
Track record
3 measurable tenures in the pay-versus-performance disclosure window. Best annualized TSR: -3.9%/yr at HRMY ( FY2020–FY2023). See the CEO track-record ranking for context.
All disclosed tenures: 7 years across 2 companies. Shown per company only: the disclosed windows overlap, so chaining them would count the same years twice.